Abstract | BACKGROUND: METHODS AND RESULTS: The Fosinopril in Acute Myocardial Infarction Study was a 2-year, randomized, double-blind, placebo-controlled, multicenter study of 285 patients with anterior acute myocardial infarction and was designed to investigate the effects of the early (<9 hours) administration of fosinopril and thrombolysis on (1) changes in echocardiographically evaluated LV volumes at 3 months and (2) long-term occurrence of death and congestive heart failure. LV volumes were normal at baseline in more than 70% of patients and were comparable between groups both at baseline and after 3 months of treatment. Fosinopril-treated patients showed a 30% reduction in the 2-year combined prevalence of death or moderate-to-severe congestive heart failure (New York Heart Association class III-IV) despite having a worse clinical profile at baseline. The benefit of fosinopril was confirmed both in patients without congestive heart failure at admission and in those with ejection fraction >40% at baseline. Moreover, the incidence of significant ventricular arrhythmias was lower in the fosinopril group (0.8% vs 6.0%, p < 0.02). CONCLUSIONS:
|
Authors | C Borghi, P Marino, P Zardini, B Magnani, S Collatina, E Ambrosioni |
Journal | American heart journal
(Am Heart J)
Vol. 136
Issue 2
Pg. 213-25
(Aug 1998)
ISSN: 0002-8703 [Print] United States |
PMID | 9704681
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Tissue Plasminogen Activator
- Fosinopril
|
Topics |
- Aged
- Angiotensin-Converting Enzyme Inhibitors
(administration & dosage, adverse effects)
- Cause of Death
- Double-Blind Method
- Drug Administration Schedule
- Echocardiography
(drug effects)
- Female
- Follow-Up Studies
- Fosinopril
(administration & dosage, adverse effects)
- Heart Failure
(diagnostic imaging, drug therapy, mortality)
- Humans
- Middle Aged
- Myocardial Infarction
(diagnostic imaging, drug therapy, mortality)
- Stroke Volume
(drug effects)
- Survival Rate
- Thrombolytic Therapy
- Tissue Plasminogen Activator
(administration & dosage)
|